PTPN22 IN T1D

Effect of PTPN22 on Treg to Teff equilibrium in human and murine autoimmune diabetes

 Coordinatore Ospedale San Raffaele 

 Organization address address: Via Olgettina 60
city: Milano
postcode: 20132

contact info
Titolo: Dr.
Nome: Maria Rosa
Cognome: Pedrazzi
Email: send email
Telefono: +39 02 2643 4845
Fax: +39 02 2643 4717

 Nazionalità Coordinatore Italy [IT]
 Totale costo 100˙000 €
 EC contributo 100˙000 €
 Programma FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
 Code Call FP7-PEOPLE-2010-RG
 Funding Scheme MC-IRG
 Anno di inizio 2011
 Periodo (anno-mese-giorno) 2011-04-01   -   2015-03-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    Ospedale San Raffaele

 Organization address address: Via Olgettina 60
city: Milano
postcode: 20132

contact info
Titolo: Dr.
Nome: Maria Rosa
Cognome: Pedrazzi
Email: send email
Telefono: +39 02 2643 4845
Fax: +39 02 2643 4717

IT (Milano) coordinator 100˙000.00
2    FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR

 Organization address address: Via Olgettina 60
city: MILANO
postcode: 20132

contact info
Titolo: Mr.
Nome: Mario
Cognome: Valsecchi
Email: send email
Telefono: +39 02 2643 2729
Fax: +39 02 26432752

IT (MILANO) participant 100˙000.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

disease    individuals    producing    models    destruction    ptpn       diabetic    susceptibility    environmental    teff    polymorphism    progression    insulin       cells    lyp    pep    murine    genetic    signaling    diabetes    selected    pre    human    functional    equilibrium    treg   

 Obiettivo del progetto (Objective)

'Type 1 diabetes (T1D) is a chronic inflammatory disease, where predisposing genetic factors along with environmental influences result in loss of immunological tolerance and destruction of insulin-producing beta cells. Genetic studies have identified three main T1D susceptibility loci, the human leukocyte antigens (HLA), insulin and most recently PTPN22, which encodes for Lyp/Pep, a lymphoid tyrosine phosphatase. A single nucleotide polymorphism (SNP) in PTPN22 at codon 620 leads to one amino-acid substitution, Arg to Trp (R620W), associated with an increase in T1D risk. A perturbation in the effector (Teff) to regulatory T cell (Treg) equilibrium seems to be implicated in T1D and most cases of autoimmunity. Functional analysis in individuals carrying the R620W polymorphism indicate a 'gain of function mutant' resulting in reduced TCR signaling. However, it is not currently known how PTPN22 is involved in mediating T1D susceptibility: effects on Treg and/or Teff thymic selection and peripheral homeostasis may be responsible. Understanding the mechanisms involved could be a key to our understanding of T1D pathogenesis. In addition, strategies that directly target Teff or Treg by inhibiting signaling from PTPN22 could be successful in halting T1D progression. The goal of this project is to analyze the role of PTPN22 on Treg and Teff equilibrium in (pre)diabetic human individuals and selected mouse models of T1D. The specific aims of this Marie-Curie RIG are: 1. Define the role of PTPN22 (R620W allele) on Treg and Teff cells in healthy versus (pre)diabetic individuals, and 2. Determine the role of PTPN22 signaling on Teff and/or Treg in two well-characterized murine models of T1D, (virally-induced [RIP-LCMV] and spontaneous [NOD]. Objectives to be achieved: 1. Functional characterization of PTPN22 mutation on Treg and Teff cells in (pre)diabetic human individuals. 2. Dissection of PTPN22 signaling in selected murine models of T1D crossed to Lyp/Pep deficient mice.'

Introduzione (Teaser)

Type 1 diabetes (T1D) is an autoimmune disease that is caused by the immune-mediated destruction of insulin-producing cells in the pancreas. Lifestyle, environmental and genetic factors seem to contribute to disease onset and progression.

Altri progetti dello stesso programma (FP7-PEOPLE)

CUL7 AND DIABETES (2011)

Role of the Cullin7 E3 ubiquitin ligase in insulin signaling and diabetes

Read More  

INFEMEC (2015)

Nanomechanics of proteins involved in viral and bacterial infections

Read More  

VIRAL&IMMUNE THERAPY (2011)

Breaking Tolerance - Combination of Virotherapy and Immunotherapy for Cancer Treatment

Read More